Estimation of lung cancer risk using homology-based emphysema quantification in patients with lung nodules.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 18 06 2018
accepted: 31 12 2018
entrez: 23 1 2019
pubmed: 23 1 2019
medline: 19 10 2019
Statut: epublish

Résumé

The purpose of this study was to assess whether homology-based emphysema quantification (HEQ) is significantly associated with lung cancer risk. This retrospective study was approved by our institutional review board. We included 576 patients with lung nodules (317 men and 259 women; age, 66.8 ± 12.3 years), who were selected from a database previously generated for computer-aided diagnosis. Of these, 283 were diagnosed with lung cancer, whereas the remaining 293 showed benign lung nodules. HEQ was performed and percentage of low-attenuation lung area (LAA%) was calculated on the basis of computed tomography scans. Statistical models were constructed to estimate lung cancer risk using logistic regression; sex, age, smoking history (Brinkman index), LAA%, and HEQ were considered independent variables. The following three models were evaluated: the base model (sex, age, and smoking history); the LAA% model (the base model + LAA%); and the HEQ model (the base model + HEQ). Model performance was assessed using receiver operating characteristic analysis and the associated area under the curve (AUC). Differences in AUCs among the models were evaluated using Delong's test. AUCs of the base, LAA%, and HEQ models were 0.585, 0.593, and 0.622, respectively. HEQ coefficient was statistically significant in the HEQ model (P = 0.00487), but LAA% coefficient was not significant in the LAA% model (P = 0.199). Delong's test revealed significant difference in AUCs between the LAA% and HEQ models (P = 0.0455). In conclusion, after adjusting for age, sex, and smoking history (Brinkman index), HEQ was significantly associated with lung cancer risk.

Identifiants

pubmed: 30668605
doi: 10.1371/journal.pone.0210720
pii: PONE-D-18-18131
pmc: PMC6342309
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0210720

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
PLoS Med. 2014 Dec 02;11(12):e1001764
pubmed: 25460915
Diagn Pathol. 2015 Apr 24;10:36
pubmed: 25907563
Chest. 2012 May;141(5):1147-1152
pubmed: 22553261
Int J Comput Assist Radiol Surg. 2017 May;12(5):767-776
pubmed: 28285338
Chest. 1988 Oct;94(4):782-7
pubmed: 3168574
Acad Radiol. 2011 Jun;18(6):661-71
pubmed: 21393027
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Int J Chron Obstruct Pulmon Dis. 2016 Sep 06;11:2125-2137
pubmed: 27660430
Med Image Anal. 2013 Jan;17(1):62-77
pubmed: 23062953
J Thorac Oncol. 2011 Jul;6(7):1200-5
pubmed: 21610523
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8829-34
pubmed: 10430855
Eur J Radiol. 2014 Dec;83(12):2268-2276
pubmed: 25445899
PLoS Med. 2017 Apr 4;14(4):e1002277
pubmed: 28376113
Ann Transl Med. 2016 Apr;4(8):151
pubmed: 27195269
Radiology. 2011 Dec;261(3):950-9
pubmed: 21900623
Lung Cancer. 2012 Jul;77(1):58-63
pubmed: 22437042
PLoS One. 2017 May 25;12(5):e0178217
pubmed: 28542398
Neuroscience. 2017 Mar 27;346:43-51
pubmed: 28077279
Eur Radiol. 2016 Feb;26(2):487-94
pubmed: 25956938

Auteurs

Mizuho Nishio (M)

Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.
Preemptive Medicine and Lifestyle-related Disease Research Center, Kyoto University Hospital, Kyoto, Kyoto, Japan.

Takeshi Kubo (T)

Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.

Kaori Togashi (K)

Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH